RCKT
$4.63
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Intraday
Recent News
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances
The broker maintains its 'outperform' rating and $16 price target on shares trading at $4.97 Wedbush Securities has reiterated its bullish stance on Rocket Pharmaceuticals, the rare disease gene therapy company, after its fourth-quarter update confirmed that patient dosing in its pivotal...
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates. Stock rises in after-hours trading.
Rocket Pharmaceuticals: Q4 Earnings Snapshot
CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. RCKT) on Thursday reported a loss of $42.5 million in its fourth quarter. On a per-share basis, the Cranbury, New Jersey-based company said it had a loss of 38 cents.
Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best single digit stocks to buy according to analysts. On January 8, Morgan Stanley lowered its price target for Rocket Pharmaceuticals from $7 to $5 while keeping an Equal Weight rating. In a 2026 group outlook, the firm noted it expects continued outperformance for US small-to-mid cap […]
Undervalued Penny Stocks To Consider In January 2026
As the U.S. stock market begins a busy week of tech earnings and interest rate decisions, major indexes have seen gains following two weeks of losses, with gold reaching new heights amid geopolitical tensions. In this context, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for investors willing to explore beyond the mainstream. Despite their vintage name, these stocks can provide significant potential for growth when backed by strong...